Conference Coverage

IMAGINE-RA: No need for MRI with treat-to-target strategy

Publish date: June 27, 2018

 

REPORTING FROM THE EULAR 2018 CONGRESS

The IMAGINE-RA study is funded by grants from the Danish Rheumatism Association and the Research Fund of Region Zealand. Funding is also provided by AbbVie via a nonrestricted grant, and adalimumab is provided free of charge. Dr. Møller-Bisgaard and coauthors had no personal conflicts of interest to declare.

SOURCE: Møller-Bisgaard S et al. EULAR 2018 Congress. Abstract OP0018.

Pages

Recommended Reading

EULAR scientific program highlights spectrum of translational research
MDedge Rheumatology
New JAK-1 inhibitor had high, early efficacy in rheumatoid arthritis trial
MDedge Rheumatology
Malignancy risk of tocilizumab and TNF inhibitors found similar
MDedge Rheumatology
Functional disability prevails despite rheumatoid arthritis treatment
MDedge Rheumatology
NIH cans study that relied on millions in funding from alcohol companies
MDedge Rheumatology
TNF inhibitor linked to one-third drop in total mortality
MDedge Rheumatology
Serum troponin predicts cardiovascular death in early arthritis
MDedge Rheumatology
Checkpoint inhibitors in autoimmune disease: More flares, better cancer outcomes
MDedge Rheumatology
Severe OA sparks depression, surgery “ameliorates” depression in RA
MDedge Rheumatology
Heart failure confers poor prognosis in rheumatoid arthritis
MDedge Rheumatology